STAT
Can we figure out how to get new drugs to the market faster?
Have you heard the oft-repeated “fact” that it takes at least 10 years from initial discovery for a new drug ...
Right to try? Drug companies can’t be forced to let terminal patients try experimental treatments
Just after her second birthday, additional testing, including an MRI of her brain and spine followed by a genetic analysis, ...
Viewpoint: Biohackers are interested in science education, not planning the ‘next global apocalypse’
Some people call me a biohacker. My colleagues like the term because it sounds cool, and journalists like it because ...
Immunotherapy dilemma: When should untested therapies be prescribed for cancer patients?
Immunotherapy is a source of great hope in cancer care. It has rescued some patients from the brink, while giving others a ...
Studies warn that CRISPR gene edits could trigger cancer
Editing cells’ genomes with CRISPR-Cas9 might increase the risk that the altered cells, intended to treat disease, will trigger cancer, two studies ...
CRISPRcon talks designer babies and scientific colonialism
While lacking the costuming of Comic-Con or revelry of SantaCon, [CRISPRCon’s] second annual geek-out dealt with a concept weightier than ...
Genes linked to schizophrenia significantly increase risk if there are pregnancy complications
Far be it from us to tell 23andMe how to run its business, but if it or any other DNA company wants ...
First Luxterna results: Does the $850,000 gene therapy work?
About eight weeks earlier, [Jack Hogan had] been the first person to get an $850,000 therapy called Luxturna since it had hit the market ...
Hemophilia gene therapies put on fast track to FDA approval
The Food and Drug Administration will soon be alerting companies that certain gene therapies in development can qualify for less ...
No male birth control due to lack of pharmaceutical industry support—not male disinterest
That the responsibility for preventing unintended pregnancy still lies almost exclusively with women remains one of the world’s great health ...
Night shift workers are at greater risk for obesity, diabetes, cancer—but why?
Researchers have been studying night workers for years, trying to better understand what happens to our circadian rhythms and our ...
Paying for pricey gene therapy without insurance: Amish community faces challenge
[A]t $850,000 a person, Luxturna was more budget-busting than just about any other drug. [Company] Spark had proposed a few different ways of helping ...
Can we recode the human genome to resist viruses?
[T]wo years in, an ambitious project to synthesize genomes — including human ones — is moving on from its shaky ...
CRISPR patent dispute is back in court. What should we expect?
It’s baaaaack, that reputation-shredding, stock-moving fight to the death over key CRISPR patents. On [April 30] in Washington, D.C., the ...
23andMe founder Anne Wojcicki: No need for experts to interpret direct-to-consumer breast and ovarian cancer tests
My company, 23andMe, recently received FDA authorization for the first ever direct-to-consumer genetic test for an inherited risk for cancer. Specifically, it tests for ...
Video: How genetics is revolutionizing medicine and disease research
This three-part series of documentary shorts, produced by Retro Report in partnership with STAT, looks back at the roots of three of ...
Highly anticipated Luxturna gene therapy for blindness costs $850,000
The trouble had started over a decade ago, when the Hogans noticed something wasn’t right with their son Jack...When they ...